BioSpace News Archive

The study demonstrated OS of 29% at 18 months with CCX872 and FOLFIRINOX combination therapy in all patients treated.

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

The net proceeds to AveXis from the offering, after deducting the underwriting discounts and commissions and other offering expenses payable by AveXis, are estimated to be approximately $431.9 million.

The Cardiovascular Research Foundation is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education.

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

DSI is a life science research company focused on delivering preclinical products, systems, services and solutions to its customers.

In addition, Stemline intends to grant the underwriters a 30-day option to purchase up to an additional 555,000 shares of its common stock offered in the public offering.

The new partnership’s efforts will take place pursuant to recent reforms by the CFDA, which include initiatives designed to accelerate drug approvals and encourage innovation, including greater alignment of China’s review process with that of the US and the EU.

Myostatin (also known as GDF8) is a key signaling protein that contributes to the regulation of muscle mass and function.

Be The Match BioTherapies®, an organization offering solutions for delivering cellular therapies, today announced that it has invested in Tmunity Therapeutics, a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy.